Symbols / ACRV $1.72 +0.88%
ACRV Chart
About
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 54.12M |
| Enterprise Value | -72.62M | Income | -81.75M | Sales | — |
| Book/sh | 4.08 | Cash/sh | 4.10 | Dividend Yield | — |
| Payout | 0.00% | Employees | 75 | IPO | — |
| P/E | — | Forward P/E | -0.93 | PEG | — |
| P/S | — | P/B | 0.42 | P/C | — |
| EV/EBITDA | 0.83 | EV/Sales | — | Quick Ratio | 8.68 |
| Current Ratio | 8.75 | Debt/Eq | 2.32 | LT Debt/Eq | — |
| EPS (ttm) | -2.12 | EPS next Y | -1.84 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-13 16:00 | ROA | -30.89% |
| ROE | -50.23% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 31.56M |
| Shs Float | 16.84M | Short Float | 17.88% | Short Ratio | 2.51 |
| Short Interest | — | 52W High | 5.65 | 52W Low | 1.05 |
| Beta | 1.80 | Avg Volume | 1.75M | Volume | 318.65K |
| Target Price | $11.50 | Recom | Buy | Prev Close | $1.70 |
| Price | $1.72 | Change | 0.88% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$11.50
Mean price target
2. Current target
$1.66
Latest analyst target
3. DCF / Fair value
$-23.32
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.66
Low
$7.00
High
$19.00
Mean
$11.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-09 | main | Piper Sandler | Overweight → Overweight | $8 |
| 2025-11-25 | reit | HC Wainwright & Co. | Buy → Buy | $19 |
| 2025-08-14 | main | Oppenheimer | Outperform → Outperform | $8 |
| 2025-05-16 | down | Jones Trading | Buy → Hold | — |
| 2025-05-15 | main | Oppenheimer | Outperform → Outperform | $9 |
| 2025-03-28 | reit | HC Wainwright & Co. | Buy → Buy | $19 |
| 2025-03-28 | main | Oppenheimer | Outperform → Outperform | $10 |
| 2025-03-26 | reit | Cantor Fitzgerald | Overweight → Overweight | — |
| 2025-03-26 | reit | Citizens Capital Markets | Market Outperform → Market Outperform | $17 |
| 2025-03-26 | main | HC Wainwright & Co. | Buy → Buy | $19 |
| 2025-01-31 | init | Cantor Fitzgerald | — → Overweight | — |
| 2024-11-14 | main | BMO Capital | Outperform → Outperform | $27 |
| 2024-11-14 | reit | HC Wainwright & Co. | Buy → Buy | $22 |
| 2024-09-16 | reit | JMP Securities | Market Outperform → Market Outperform | $17 |
| 2024-09-16 | up | Ladenburg Thalmann | Neutral → Buy | $16 |
| 2024-09-16 | reit | BMO Capital | Outperform → Outperform | $28 |
| 2024-09-16 | reit | HC Wainwright & Co. | Buy → Buy | $22 |
| 2024-08-13 | reit | HC Wainwright & Co. | Buy → Buy | $22 |
| 2024-05-15 | reit | BMO Capital | Outperform → Outperform | $25 |
| 2024-05-14 | main | HC Wainwright & Co. | Buy → Buy | $22 |
- Cancer drug combo clears tumors in mice in Acrivon study - Stock Titan ue, 17 Mar 2026 21
- Acrivon Therapeutics Inc. (ACRV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade Sat, 14 Mar 2026 00
- $ACRV stock is down 16% today. Here's what we see in our data. - Quiver Quantitative Fri, 27 Feb 2026 08
- Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's Why - Yahoo Finance ue, 03 Mar 2026 17
- Acrivon Stock Sinks 29% Despite Positive Phase 2b Endometrial Cancer Data - Nasdaq hu, 08 Jan 2026 08
- Acrivon Therapeutics, Inc. (ACRV) Presents at ESGO 27th Annual Congress 2026 - Slideshow - Seeking Alpha Wed, 04 Mar 2026 23
- Acrivon Therapeutics stock plunges after mixed cancer trial results - Investing.com hu, 08 Jan 2026 08
- Acrivon Therapeutics Stock (ACRV) Sinks despite Positive Cancer Trial Results - TipRanks hu, 08 Jan 2026 08
- New data on experimental cancer drugs ACR-368 and ACR-2316 coming - Stock Titan ue, 06 Jan 2026 08
- H.C. Wainwright Initiates Coverage on Acrivon Therapeutics (ACRV) With “Buy” Rating and $19 PT - Yahoo Finance Fri, 28 Nov 2025 08
- Acrivon Therapeutics (ACRV) CFO granted 132,925 stock options in new award - Stock Titan ue, 03 Mar 2026 08
- Insider Purchase: President and CEO of $ACRV Buys 49,000 Shares - Quiver Quantitative Fri, 16 Jan 2026 08
- Co-Founder of Acrivon Therapeutics Peter Blume-Jensen Buys 2.6% More Shares - Yahoo Finance Sun, 18 Jan 2026 08
- New cancer drugs show tumor shrinkage in early trials - Stock Titan hu, 08 Jan 2026 08
- Acrivon Therapeutics Stock (ACRV) Opinions on Clinical Data Release - Quiver Quantitative hu, 08 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 49000 | 82124 | — | Purchase at price 1.68 per share. | BLUME-JENSEN PETER | Chief Executive Officer | — | 2026-01-14 00:00:00 | I |
| 1 | 8832 | 14999 | — | Purchase at price 1.70 per share. | LEVY ADAM D. | Chief Financial Officer | — | 2026-01-14 00:00:00 | D |
| 2 | 10000 | 17218 | — | Purchase at price 1.72 per share. | DEVROE ERIC | Chief Operating Officer | — | 2026-01-13 00:00:00 | D |
| 3 | 736767 | 1017919 | — | Sale at price 1.34 - 1.41 per share. | PERCEPTIVE ADVISORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-05-01 00:00:00 | I |
| 4 | 1519952 | 2744946 | — | Sale at price 1.41 - 1.95 per share. | PERCEPTIVE ADVISORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-04-29 00:00:00 | I |
| 5 | 10000 | 10400 | — | Conversion of Exercise of derivative security at price 1.04 per share. | DEVROE ERIC | Chief Operating Officer | — | 2024-05-17 00:00:00 | D |
| 6 | 2353000 | 20000500 | — | Purchase at price 8.50 per share. | PERCEPTIVE ADVISORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | — | 2024-04-11 00:00:00 | I |
| 7 | 3530000 | 30005000 | — | Stock Award(Grant) at price 8.50 per share. | RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | — | 2024-04-11 00:00:00 | I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -88.19M | -66.57M | -32.29M | -16.15M |
| TotalUnusualItems | -80.00K | |||
| TotalUnusualItemsExcludingGoodwill | -80.00K | |||
| NetIncomeFromContinuingOperationNetMinorityInterest | -80.56M | -60.39M | -31.17M | -16.24M |
| ReconciledDepreciation | 1.01M | 536.00K | 364.00K | 37.00K |
| EBITDA | -88.19M | -66.57M | -32.29M | -16.15M |
| EBIT | -89.20M | -67.10M | -32.66M | -16.18M |
| NetInterestIncome | 9.20M | 7.04M | ||
| InterestIncome | 9.20M | 7.04M | ||
| NormalizedIncome | -80.56M | -60.39M | -31.17M | -16.24M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -80.56M | -60.39M | -31.17M | -16.24M |
| TotalExpenses | 89.20M | 67.10M | 32.66M | 16.18M |
| TotalOperatingIncomeAsReported | -89.20M | -67.10M | -32.66M | -16.18M |
| DilutedAverageShares | 33.79M | 22.08M | 4.12M | 12.91M |
| BasicAverageShares | 33.79M | 22.08M | 4.12M | 12.91M |
| DilutedEPS | -2.38 | -2.74 | -7.56 | -1.26 |
| BasicEPS | -2.38 | -2.74 | -7.56 | -1.26 |
| DilutedNIAvailtoComStockholders | -80.56M | -60.39M | -31.17M | -16.24M |
| NetIncomeCommonStockholders | -80.56M | -60.39M | -31.17M | -16.24M |
| NetIncome | -80.56M | -60.39M | -31.17M | -16.24M |
| NetIncomeIncludingNoncontrollingInterests | -80.56M | -60.39M | -31.17M | -16.24M |
| NetIncomeContinuousOperations | -80.56M | -60.39M | -31.17M | -16.24M |
| PretaxIncome | -80.56M | -60.39M | -31.17M | -16.24M |
| OtherIncomeExpense | -558.00K | -322.00K | 1.49M | -59.00K |
| OtherNonOperatingIncomeExpenses | -558.00K | -322.00K | 1.49M | -59.00K |
| GainOnSaleOfSecurity | -80.00K | |||
| NetNonOperatingInterestIncomeExpense | 9.20M | 7.04M | ||
| InterestIncomeNonOperating | 9.20M | 7.04M | ||
| OperatingIncome | -89.20M | -67.10M | -32.66M | -16.18M |
| OperatingExpense | 89.20M | 67.10M | 32.66M | 16.18M |
| ResearchAndDevelopment | 63.99M | 46.02M | 23.95M | 13.72M |
| SellingGeneralAndAdministration | 25.21M | 21.08M | 8.71M | 2.47M |
| GeneralAndAdministrativeExpense | 25.21M | 21.08M | 8.71M | 2.47M |
| OtherGandA | 7.11M | 6.46M | 3.64M | 1.10M |
| SalariesAndWages | 18.10M | 14.62M | 5.07M | 1.37M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 31.23M | 22.52M | 21.92M | 18.81M |
| ShareIssued | 31.23M | 22.52M | 21.92M | 18.81M |
| TotalDebt | 3.65M | 4.64M | 4.96M | 5.63M |
| TangibleBookValue | 176.79M | 121.19M | 170.47M | -23.81M |
| InvestedCapital | 176.79M | 121.19M | 170.47M | -23.81M |
| WorkingCapital | 164.41M | 116.39M | 125.58M | 97.49M |
| NetTangibleAssets | 176.79M | 121.19M | 170.47M | -23.81M |
| CapitalLeaseObligations | 3.65M | 4.64M | 4.96M | 5.63M |
| CommonStockEquity | 176.79M | 121.19M | 170.47M | -23.81M |
| TotalCapitalization | 176.79M | 121.19M | 170.47M | -23.81M |
| TotalEquityGrossMinorityInterest | 176.79M | 121.19M | 170.47M | -23.81M |
| StockholdersEquity | 176.79M | 121.19M | 170.47M | -23.81M |
| GainsLossesNotAffectingRetainedEarnings | 447.00K | -83.00K | -95.00K | 0.00 |
| OtherEquityAdjustments | 447.00K | -83.00K | -95.00K | |
| RetainedEarnings | -196.98M | -116.42M | -56.03M | -24.86M |
| AdditionalPaidInCapital | 373.28M | 237.68M | 226.58M | 1.05M |
| CapitalStock | 31.00K | 23.00K | 22.00K | 2.00K |
| CommonStock | 31.00K | 23.00K | 22.00K | 2.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 19.80M | 17.07M | 10.75M | 130.40M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 2.59M | 3.77M | 4.24M | 127.48M |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 122.52M | ||
| DerivativeProductLiabilities | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 2.59M | 3.77M | 4.24M | 4.96M |
| LongTermCapitalLeaseObligation | 2.59M | 3.77M | 4.24M | 4.96M |
| CurrentLiabilities | 17.21M | 13.30M | 6.52M | 2.91M |
| CurrentDeferredLiabilities | 0.00 | 69.00K | 66.00K | |
| CurrentDeferredRevenue | 0.00 | 69.00K | 66.00K | |
| CurrentDebtAndCapitalLeaseObligation | 1.06M | 877.00K | 726.00K | 664.00K |
| CurrentCapitalLeaseObligation | 1.06M | 877.00K | 726.00K | 664.00K |
| CurrentNotesPayable | 0.00 | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 5.46M | 3.86M | 2.66M | 667.00K |
| PayablesAndAccruedExpenses | 10.70M | 8.57M | 3.06M | 1.52M |
| CurrentAccruedExpenses | 9.94M | 3.52M | 2.15M | 553.00K |
| Payables | 758.00K | 5.05M | 904.00K | 964.00K |
| AccountsPayable | 758.00K | 5.05M | 904.00K | 964.00K |
| TotalAssets | 196.59M | 138.26M | 181.23M | 106.59M |
| TotalNonCurrentAssets | 14.96M | 8.57M | 49.13M | 6.18M |
| OtherNonCurrentAssets | 198.00K | 414.00K | 388.00K | 388.00K |
| NonCurrentDeferredAssets | 1.65M | 251.00K | 0.00 | |
| InvestmentsAndAdvances | 5.09M | 0.00 | 41.88M | 0.00 |
| InvestmentinFinancialAssets | 5.09M | 0.00 | ||
| AvailableForSaleSecurities | 5.09M | |||
| NetPPE | 8.03M | 7.91M | 6.86M | 5.79M |
| AccumulatedDepreciation | -1.96M | -956.00K | -420.00K | -56.00K |
| GrossPPE | 9.99M | 8.86M | 7.28M | 5.85M |
| ConstructionInProgress | 58.00K | 1.31M | 0.00 | |
| OtherProperties | 3.55M | 4.43M | 4.77M | 5.50M |
| MachineryFurnitureEquipment | 6.38M | 3.13M | 2.51M | 346.00K |
| CurrentAssets | 181.63M | 129.69M | 132.09M | 100.41M |
| OtherCurrentAssets | 2.15M | 2.23M | 4.34M | 805.00K |
| PrepaidAssets | 805.00K | |||
| CashCashEquivalentsAndShortTermInvestments | 179.48M | 127.46M | 127.75M | 99.60M |
| OtherShortTermInvestments | 139.66M | 91.44M | 98.23M | 0.00 |
| CashAndCashEquivalents | 39.82M | 36.02M | 29.52M | 99.60M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -68.44M | -43.93M | -32.28M | -14.22M |
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 70.00M | 0.00 | 104.46M | 112.22M |
| CapitalExpenditure | -2.77M | -1.29M | -2.17M | -238.00K |
| EndCashPosition | 40.02M | 36.43M | 29.91M | 99.99M |
| BeginningCashPosition | 36.43M | 29.91M | 99.99M | 1.99M |
| ChangesInCash | 3.59M | 6.52M | -70.08M | 98.00M |
| FinancingCashFlow | 121.03M | -1.55M | 101.71M | 112.22M |
| CashFlowFromContinuingFinancingActivities | 121.03M | -1.55M | 101.71M | 112.22M |
| NetOtherFinancingCharges | -9.06M | -2.33M | -2.77M | |
| ProceedsFromStockOptionExercised | 60.09M | 775.00K | 24.00K | 1.00K |
| NetPreferredStockIssuance | 0.00 | 112.22M | ||
| PreferredStockIssuance | 0.00 | 112.22M | ||
| NetCommonStockIssuance | 70.00M | 0.00 | 104.46M | 0.00 |
| CommonStockIssuance | 70.00M | 0.00 | 104.46M | 0.00 |
| NetIssuancePaymentsOfDebt | 0.00 | |||
| NetShortTermDebtIssuance | 0.00 | |||
| ShortTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -51.77M | 50.72M | -141.68M | -238.00K |
| CashFlowFromContinuingInvestingActivities | -51.77M | 50.72M | -141.68M | -238.00K |
| NetInvestmentPurchaseAndSale | -49.00M | 52.01M | -139.51M | 0.00 |
| SaleOfInvestment | 153.92M | 108.53M | 10.67M | 0.00 |
| PurchaseOfInvestment | -202.93M | -56.53M | -150.18M | 0.00 |
| NetPPEPurchaseAndSale | -2.77M | -1.29M | -2.17M | -238.00K |
| PurchaseOfPPE | -2.77M | -1.29M | -2.17M | -238.00K |
| OperatingCashFlow | -65.67M | -42.64M | -30.12M | -13.98M |
| CashFlowFromContinuingOperatingActivities | -65.67M | -42.64M | -30.12M | -13.98M |
| ChangeInWorkingCapital | 2.44M | 8.14M | -1.53M | 328.00K |
| ChangeInOtherCurrentLiabilities | -1.05M | -754.00K | -667.00K | -572.00K |
| ChangeInOtherCurrentAssets | -1.18M | 0.00 | ||
| ChangeInPayablesAndAccruedExpense | 4.43M | 6.78M | 2.67M | 1.66M |
| ChangeInAccruedExpense | 8.02M | 3.17M | 2.92M | 866.00K |
| ChangeInPayable | -3.59M | 3.61M | -245.00K | 798.00K |
| ChangeInAccountPayable | -3.59M | 3.61M | -245.00K | 798.00K |
| ChangeInPrepaidAssets | 237.00K | 2.11M | -3.54M | -764.00K |
| OtherNonCashItems | 932.00K | 778.00K | 731.00K | 1.14M |
| StockBasedCompensation | 14.29M | 11.62M | 2.19M | 497.00K |
| AmortizationOfSecurities | -3.78M | -3.32M | -698.00K | 0.00 |
| DepreciationAmortizationDepletion | 1.01M | 536.00K | 364.00K | 37.00K |
| DepreciationAndAmortization | 1.01M | 536.00K | 364.00K | 37.00K |
| Depreciation | 1.01M | 536.00K | 364.00K | 37.00K |
| OperatingGainsLosses | 255.00K | |||
| GainLossOnInvestmentSecurities | 313.00K | |||
| NetIncomeFromContinuingOperations | -80.56M | -60.39M | -31.17M | -16.24M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ACRV
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|